Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults
Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults
Enrolling by invitation · NCT06782958 · Registry updated 2025-01-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Enrolling by invitation | Phase 1 | 2025-01-20 | NCT06782958 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Hospital of Lanzhou University | Lanzhou | China | 3 |